These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 18495268

  • 21. Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?
    Omerovic E, Waagstein F, Swedberg K.
    Eur J Heart Fail; 2010 Apr; 12(4):313-4. PubMed ID: 20335348
    [No Abstract] [Full Text] [Related]

  • 22. Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence?
    Wikström BG.
    Eur J Heart Fail; 2010 Aug; 12(8):893. PubMed ID: 20675671
    [No Abstract] [Full Text] [Related]

  • 23. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
    García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-González P, Muñoz MB.
    Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
    [Abstract] [Full Text] [Related]

  • 24. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.
    Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
    [Abstract] [Full Text] [Related]

  • 25. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
    Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT.
    Am J Cardiol; 2005 Aug 01; 96(3):423-6. PubMed ID: 16054474
    [Abstract] [Full Text] [Related]

  • 26. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S, Cetin M, Ciçekçioğlu H, Uçar O, Çetin ZG, Ozuğuz U, Bakır F, Berker D, Güler S.
    Anadolu Kardiyol Derg; 2011 Sep 01; 11(6):523-9. PubMed ID: 21821501
    [Abstract] [Full Text] [Related]

  • 27. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L, Cui L, Wei JP, Li GP, Qi GX, Hao YM, Wang WZ, Li HM, Liu J, Jiang DJ, Zhang YD.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun 01; 38(6):527-30. PubMed ID: 21033135
    [Abstract] [Full Text] [Related]

  • 28. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T, Gegenhuber A, Haltmayer M.
    Int J Cardiol; 2005 Oct 10; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract] [Full Text] [Related]

  • 29. [Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
    Xu ZD, He WX, Zhao YF, Xia SX, He B, Yang T, Cao DX, Peng SL, Li J, Cao MH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct 10; 29(10):2027-9. PubMed ID: 19861257
    [Abstract] [Full Text] [Related]

  • 30. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
    Parissis JT, Farmakis D, Kremastinos DT.
    Eur J Heart Fail; 2006 Mar 10; 8(2):215; author reply 218. PubMed ID: 16442844
    [No Abstract] [Full Text] [Related]

  • 31. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B.
    J Card Fail; 2007 Aug 10; 13(6):417-21. PubMed ID: 17675054
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [The novelty in the treatment of heart failure].
    Reingardiene D.
    Medicina (Kaunas); 2005 Aug 10; 41(7):625-31. PubMed ID: 16062032
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
    Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT.
    Am J Cardiol; 2007 Jan 01; 99(1):146-7. PubMed ID: 17196480
    [No Abstract] [Full Text] [Related]

  • 36. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G, Kremastinos DT.
    Am J Cardiol; 2008 Nov 01; 102(9):1225-9. PubMed ID: 18940297
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.
    J Am Coll Cardiol; 2009 Jun 23; 53(25):2343-8. PubMed ID: 19539144
    [Abstract] [Full Text] [Related]

  • 39. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R.
    Eur J Heart Fail; 2005 Dec 23; 7(7):1156-63. PubMed ID: 16084762
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.